Literature DB >> 26603624

Cognitive Impairment in Schizophrenia: Interplay of BDNF and Childhood Trauma? A Review of Literature.

Geetanjali Sahu1, Kishor Malavade1,2, Theresa Jacob3.   

Abstract

Cognitive impairment is a core feature of schizophrenia. These deficits can also serve as an endophenotype for the illness in genetic studies. There is evidence that suggests that cognition can be considered a reasonable target for intervention in both schizophrenia and bipolar disorder. One of the most studied genetic phenotypes for psychosis is brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms. BDNF has an established role in neuronal development and cell survival in response to stress and is abnormally expressed in schizophrenia. Studies have shown that childhood trauma is associated with poor prognosis of schizophrenic patients. BDNF-Val66Met polymorphism has been shown to moderate the impact of childhood adversity on later expression of affective symptoms, suggesting the possibility of gene environment interactions. Considering the recent advances of neuroscience an up to date review of relevant literature is warranted in this field. This article reviews the current literature available regarding associations between the Val66Met polymorphism, childhood trauma and cognitive dysfunction in schizophrenia.

Entities:  

Keywords:  BDNF; BDNFval66met polymorphism; Childhood trauma; Cognition in schizophrenia; Endophenotype; Genetics

Mesh:

Substances:

Year:  2016        PMID: 26603624     DOI: 10.1007/s11126-015-9409-8

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  29 in total

1.  Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis.

Authors:  B S Fernandes; M Berk; C W Turck; J Steiner; C-A Gonçalves
Journal:  Mol Psychiatry       Date:  2013-12-17       Impact factor: 15.992

2.  Hippocampal interneurons are abnormal in schizophrenia.

Authors:  Christine Konradi; C Kevin Yang; Eric I Zimmerman; Kathryn M Lohmann; Paul Gresch; Harry Pantazopoulos; Sabina Berretta; Stephan Heckers
Journal:  Schizophr Res       Date:  2011-07-13       Impact factor: 4.939

3.  Transport of brain-derived neurotrophic factor across the blood-brain barrier.

Authors:  W Pan; W A Banks; M B Fasold; J Bluth; A J Kastin
Journal:  Neuropharmacology       Date:  1998-12       Impact factor: 5.250

4.  Mineralocorticoid receptor genotype moderates the association between physical neglect and serum BDNF.

Authors:  Andressa Bortoluzzi; Giovanni Abrahão Salum; Carolina Blaya; Patrícia Pelufo Silveira; Rodrigo Grassi-Oliveira; Eduarda Dias da Rosa; Bianca Wollenhaupt de Aguiar; Laura Stertz; Vera Lúcia Bosa; Ilaine Schuch; Marcelo Goldani; Flavio Kapczinski; Sandra Leistner-Segal; Gisele Gus Manfro
Journal:  J Psychiatr Res       Date:  2014-09-11       Impact factor: 4.791

5.  Interplay between childhood trauma and BDNF val66met variants on blood BDNF mRNA levels and on hippocampus subfields volumes in schizophrenia spectrum and bipolar disorders.

Authors:  Monica Aas; Unn K Haukvik; Srdjan Djurovic; Martin Tesli; Lavinia Athanasiu; Thomas Bjella; Lars Hansson; Annamaria Cattaneo; Ingrid Agartz; Ole A Andreassen; Ingrid Melle
Journal:  J Psychiatr Res       Date:  2014-08-30       Impact factor: 4.791

6.  Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety.

Authors:  J M Gatt; C B Nemeroff; C Dobson-Stone; R H Paul; R A Bryant; P R Schofield; E Gordon; A H Kemp; L M Williams
Journal:  Mol Psychiatry       Date:  2009-01-20       Impact factor: 15.992

7.  A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS.

Authors:  Binith Cheeran; Penelope Talelli; Francesco Mori; Giacomo Koch; Antonio Suppa; Mark Edwards; Henry Houlden; Kailash Bhatia; Richard Greenwood; John C Rothwell
Journal:  J Physiol       Date:  2008-10-09       Impact factor: 5.182

8.  Prevalence of bullying victimisation amongst first-episode psychosis patients and unaffected controls.

Authors:  Antonella Trotta; Marta Di Forti; Valeria Mondelli; Paola Dazzan; Carmine Pariante; Anthony David; Alice Mulè; Laura Ferraro; Ivan Formica; Robin M Murray; Helen L Fisher
Journal:  Schizophr Res       Date:  2013-07-26       Impact factor: 4.939

9.  Brain derived Neurotropic Factor (BDNF) is associated with childhood abuse but not cognitive domains in first episode psychosis.

Authors:  Christos Theleritis; Helen L Fisher; Ingo Shäfer; Laura Winters; Daniel Stahl; Craig Morgan; Paola Dazzan; Josefien Breedvelt; Irene Sambath; Silia Vitoratou; Manuela Russo; Abraham Reichenberg; M Aurora Falcone; Valeria Mondelli; Jennifer O'Connor; Anthony David; Philip McGuire; Carmine Pariante; Marta Di Forti; Robin M Murray; Stefania Bonaccorso
Journal:  Schizophr Res       Date:  2014-09-22       Impact factor: 4.939

10.  Brain-derived neurotrophic factor/FK506-binding protein 5 genotype by childhood trauma interactions do not impact on hippocampal volume and cognitive performance.

Authors:  Dennis Hernaus; Ruud van Winkel; Ed Gronenschild; Petra Habets; Gunter Kenis; Machteld Marcelis; Jim van Os; Inez Myin-Germeys; Dina Collip
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more
  1 in total

1.  A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia.

Authors:  Wei Yin; David Han; Polyna Khudyakov; Rhett Behrje; Joel Posener; Antonio Laurenza; Dimitrios Arkilo
Journal:  Br J Clin Pharmacol       Date:  2022-04-17       Impact factor: 3.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.